前沿生物: 北京国枫（南京）律师事务所关于前沿生物药业（南京）股份有限公司2024年年度股东大会的法律意见书

Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications of attendees, and voting results of the 2024 Annual General Meeting of Frontier Biopharmaceuticals (Nanjing) Co., Ltd. [1][2][7] Meeting Procedures - The meeting was convened by the company's fourth board of directors and publicly announced on April 30, 2025, detailing the time, location, and agenda [2][3] - The meeting was held on May 23, 2025, at Nanjing Jiayue Yinh Lake Hotel, combining on-site and online voting methods [3][4] Attendee Qualifications - A total of 93 shareholders (or their proxies) attended the meeting, representing 173,180,166 shares, which is 46.2333% of the total voting shares [4] Voting Procedures and Results - The meeting reviewed and voted on all agenda items as per the notice, with results indicating that all items except one were passed by a majority [5][6][7] - Specific voting results included: - The proposal for the 2024 Annual Report was passed with 106,143 shares abstaining, representing 0.0614% of valid votes [5] - The proposal for the 2025 Financial Budget Report was passed with 214,145 shares abstaining, representing 0.1238% of valid votes [5] - The proposal for the 2024 Profit Distribution Plan was passed with 1,104,115 shares opposing [5] - The proposal for the authorization of the board to issue shares was passed with 1,524,109 shares opposing [6]